Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MDX-1401 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MDX-1401 | EXPERIMENTAL | MDX-1401 iv at various doses |
| Name | Type | Description |
|---|---|---|
| MDX-1401 | BIOLOGICAL | IV weekly for 4 weeks |
Inclusion Criteria: * Diagnosis of CD30-positive HL by immunohistochemistry or flow cytometry * Must have failed or relapsed following second line chemotherapy or radiation or failed/relapsed following autologous stem cell transplant * Bi-measurable disease * ECOG Performance Status of 0 - 2 * Meet...
MDX-1401 is an investigational monoclonal antibody developed by Bristol-Myers Squibb for the treatment of Hodgkin's lymphoma. It was studied in a Phase 1 clinical trial in patients with CD30-positive refractory or relapsed Hodgkin's lymphoma. It is not an approved therapy and remains in clinical development.
MDX-1401 was studied as a treatment for CD30-positive refractory or relapsed Hodgkin's lymphoma. The Phase 1 trial enrolled patients with this condition, including adolescents as young as 12 years old. It is an investigational agent and has not been approved for any use.
MDX-1401 is developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 study of the antibody in Hodgkin's lymphoma.
MDX-1401 is in Phase 1 development. A single Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not received FDA approval.
MDX-1401 was evaluated in one Phase 1 clinical trial, NCT00634452, titled "Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma." The trial enrolled 22 patients in the United States and is now completed. It was an uncontrolled study without randomization or blinding.